COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information.

Population cancer patients global guidance languages vaccination

Journal

Reviews on recent clinical trials
ISSN: 1876-1038
Titre abrégé: Rev Recent Clin Trials
Pays: United Arab Emirates
ID NLM: 101270873

Informations de publication

Date de publication:
2022
Historique:
received: 27 05 2021
revised: 16 07 2021
accepted: 26 08 2021
pubmed: 31 12 2021
medline: 25 5 2022
entrez: 30 12 2021
Statut: ppublish

Résumé

Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations. Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries. A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population. Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.

Sections du résumé

BACKGROUND
Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations.
METHODS
Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries.
RESULTS
A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population.
CONCLUSION
Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.

Identifiants

pubmed: 34967300
pii: RRCT-EPUB-118603
doi: 10.2174/1574887116666211028145848
pmc: PMC9241076
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-14

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Références

Lancet Oncol. 2020 Jun;21(6):759-760
pubmed: 32410877

Auteurs

Davide Mauri (D)

Department Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.

Konstantinos Kamposioras (K)

Department. Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Lampriani Tsali (L)

PACMeR Evidence Based Medicine, Athens, Greece.

Mario Dambrosio (M)

Department. Medical Oncology, Clinica San Carlo, Paderno Dugnano, Milano Italy.

Berardino De Bari (B)

Service Radio-Oncologie Neuchâtel Hôpital Network, La Chaux-de-Fonds, Switzerland.

Nadia Hindi (N)

Department. Medical Oncology, Fundación Jimenez Díaz University Hospital, Madrid, Spain.

Carl Salembier (C)

Radiation Oncology Department, Europe Hospitals, Brussels, Belgium.

Joanna Nixon (J)

Beatson West of Scotland Cancer Center, Strathclyde University, Glasgow, UK.

Tzachanis Dimitrios (T)

UCSD Blood and Marrow Transplant Program, UCSD/Moores Cancer Center, La Jolla, CA, USA.

Flippo Alongi (F)

Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria, Negrar-Verona,University of Brescia, Verona, Italy.

Hassan Hameed (H)

The Christie NHS Foundation Trust, Manchester UK, The Christie\'s Hospital, Manchester, UK.

Antonios Valachis (A)

Department Medical Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Antonios, Sweden.

Konstantinos Papadimitriou (K)

Department of Medical Oncology, University Hospital of Antwerp, Antwerp, Belgium.

Stefanie Corradini (S)

Department Radiation Oncology, University Hospital, LMU Munich, Germany.

Lazar Popovic (L)

Department Medical Oncology,Oncology Institute of Vojvodina, University of Novi Sad, Serbia.

Jindrich Kopecky (J)

Department Oncology and Radiotherapy, Charles University, Hradec Králové, Prague, Czech Republic.

Andres Rodriguez (A)

Medical Oncology, Instituto Alexander Fleming in Buenos Aires, Buenos Aires, Argentina.

Katarina Antunac (K)

University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.

Junlin Yi (J)

Department Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

Jozsef Lovey (J)

National Institute of Oncology, Semmelweis University, Budapest, Hungary.

Primoz Strojan (P)

Department Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia.

Haytham Saraireh (H)

Department Radiation Oncology, Royal Medical Service, Amman, Jordan.

Ranveig Røtterud (R)

Cell Biologist, CEO Bladder Cancer, Oslo, Norway.

Marzanna Chojnacka (M)

Department of Oncology and Radiotherapy, Maria Skłodowska- Curie National Research Institute of Oncology, Warsaw, Poland.

Santa Cruz Olalla (SC)

Service de Radio-Oncologie, Neuchâtel Hôpital Network, La Chaux-de-Fonds, Switzerland.

Natalia Chilingirova (N)

Department Medical Oncology, Center of Excellence, Heart and Brain Hospital Pleven, Medical University Pleven, Bulgaria.

Ramon Andrade De Mello (RA)

Department Medical Oncology Escola Paulista de Medicina, Federal University of São Paulo, Brazil.
Department Biomedical Sciences,and Medicine, University of Algarve, Faro, Portugal.

Giovanna Araujo Amaral (GA)

Department Medical Oncology, Escola Paulista de Medicina, Federal University of São Paulo, Brazil.

Farsid Arbabi (F)

Department Medical Oncology, Rooshana Cancer Center, Tehran, Iran.

Radu Vidra (R)

Medical Oncology, Regional Institute of Gastroenterology and Hepatology "Prof. Dr. O. Fodor", Cluj-Napoca, Romania.

Erjeta Rapushi (E)

Department Medical Oncology, Berat Regional Hospital, Berat, Albania.

Dan Takeuchi (D)

Matsudo City General Hospital, Chiba, Japan.

Chirstos Christopoulos (C)

Service de Radiothérapie Oncologique, GHT Grand Paris Nord-Est. G.H.I Le Raincy -Montfermeil, France.

Irina Ivanova (I)

Murmansk Branch of All-Russian Association of Cancer Patients "Zdravstvuy", NGO Center of Initiatives Support, Murmansk, Russia.

Igor Djan (I)

Department for Radiosurgery and SBRT, Clinical center of Serbia, Belgrade, Serbia.

Branka Petricevic (B)

Department of Medical Oncology and Hematology,Wilhelminenspital, Vienna, Austria.

Francesco Cellini (F)

Radioterapia Oncologica-Fondazione Policlinico A. Gemelli, IRCCS -Rome, Italy.

Iglika Mihaylova (I)

Department of Radiotherapy,Specialized Hospital for Active Treatment in Oncology "Plovdivsko pole", Sofia, Bulgaria.

Natalija Dedic Plavetic (ND)

Department of Oncology, University Hospital Centre Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia.

Cvetka Grašič Kuhar (CG)

Department Medical Oncology, Institute of Oncology, Ljubljana, Slovenia.

Elena Takeuchi (E)

The Christie NHS Foundation Trust, Manchester, UK.

Pantelis Kountourakis (P)

Department Medical Oncology,Bank of Cyprus Oncology Centre, Nicosia, Cyprus.

Panagiotis Ntellas (P)

Department Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.

Ioanna Gazouli (I)

Department Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.

Stefania Gkoura (S)

Department Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.

Salih Yuce (S)

Chairmen of the Board-Young Saving Association, Turkey.

Özlem Er (Ö)

Acıbadem University, Faculty of Medicine, Turkey.

Chait Yasmina (C)

Service de Haematologie, GHT Grand Paris Nord-Est. G.H.I Le Raincy -Montfermeil, France GHT Grand Paris Nord-Est, G.H.I Le Raincy -Montfermeil, France.

Gireesh Kumaran (G)

Medical Oncology, Auckland Regional Cancer and Blood Service, Auckland, New Zealand.

Orges Spahiu (O)

Radiation Therapy Unit, University Hospital Center "Mother Teresa", Tirana, Albania.

Aasim Yusuf (A)

Gastroenterology, Acting CEO Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore and Peshawar Pakistan.

Paulina Gono (P)

ECPC Partneships and Communication Officer, Belgium.

Kathi Apostolidis (K)

ECPC President ,Belgium.

Maria Tolia (M)

Department. Radiation Oncology, University Hospital of Heraklion, Crete, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH